Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioSphere Benefits From Broader UFE Awareness, But Remains Short On Profit

This article was originally published in The Gray Sheet

Executive Summary

Uterine fibroid embolic device maker BioSphere Medical credits Q4 revenue growth to a series of favorable technology assessments, improved marketing management and a high-profile procedure

You may also be interested in...

People In Brief

American Medical Systems: Martin Emerson assumes Minnetonka, Minn. firm's president & CEO spot effective Jan. 5, replacing Douglas Kohrs, who will remain chairman of AMS' board. A 20-year device industry veteran, Emerson has spent his last four years at American Medical Systems in various executive roles, including VP-general manager of international, exec VP-global sales & marketing and chief operating officer. His previous career experience includes stints at Baxter International and Boston Scientific. Currently, AMS is preparing a PMA supplement for its TherMatrx TMx-2000 BPH thermotherapy system (1"The Gray Sheet" Nov. 8, 2004, p. 6)...

InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required

FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission

Biocompatibles’ Drug-Eluting UFE Treatment Would Be Marketed By Terumo

Biocompatibles International may await development of a drug-eluting version of its Bead Block microspheres therapy before seeking FDA clearance for uterine fibroid embolization (UFE)

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts